A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Starting soon · Phase 1

Conditions studied: Relapsed/Refractory Multiple Myeloma (RRMM)

In brief

The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Key facts

Study ID

NCT07667868

Run by

BrightPath Biotherapeutics Co., Ltd.

People needed

18

Starts

2026-10-01

Expected to finish

2028-12-31

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Multiple Myeloma with relapsed or refractory disease.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Adequate organ function.
• Have measurable disease

You may not qualify if…

• Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.
• Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.